AlphAIAlphAI — Financial news for AI agents
investing.comOCT 201 min read$SRRK

Truist reiterates Buy on Scholar Rock stock, cites uptake potential

Truist Securities reiterated a Buy rating and $77 price target for Scholar Rock (SRRK), citing potential uptake of its Isembyld treatment for spinal muscular atrophy. Analysts expect 50-60% of patients to use the drug within five years, with key opinion leaders validating trial results and noting functional improvements. The stock trades at $41.14, with a Strong Buy consensus and price targets ranging from $58 to $84.

Original reporting
investing.com
Published Oct 20, 2026, 2:14 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 20, 2026, 2:32 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefFinancial news
Primary signal
$SRRK
Bullish
medium confidence
Mentioned
$SRRK
Relevance
4/10
AlphAI data visualization · based on investing.com
Decision brief

The 30-second read

$SRRKBullishLow
01

Why it matters

The higher price target and Buy rating could attract short‑term buying, but execution risk remains.

02

Market read

Analyst upgrade may provide a modest catalyst for SRRK and related biotech peers.

03

What to watch

Reimbursement uncertainty and fracture‑risk concerns could temper upside.

Relevance 4/10Novelty 2/10Timing: today

Background

Analyst houses reiterated bullish views on Scholar Rock after recent key opinion leader feedback on its SMA drug.

Company-level read

Ticker impact

$SRRKBullishMedium confidence
Context

Truist reiterated a Buy rating and raised its price target to $77 for Scholar Rock, citing new feedback from key opinion leaders on its Isembyld SMA treatment.

Expected impact

likely upward pressure as traders price in the higher target and positive clinical feedback

Evidence & confidence

The upgrade is fresh and includes a specific price target, which can influence short‑term demand.

Market effects

Sector

Positive sentiment may lift other biotech stocks focused on rare disease therapies.

Regional

US biotech sector could see modest gains.

Global

Limited to investors tracking US-listed biotech.

Counterpoint

What could challenge this read

The upgrade may be premature if trial data does not translate into commercial sales.

Key entities

  • analyst
    Truist Securities

    Reiterated Buy rating and $77 price target for SRRK.

  • company
    Scholar Rock

    Biotech firm developing Isembyld for spinal muscular atrophy.

Read at source← All news

Related articles

OCT 16
$IONSHighAI 8/10

FDA Drug Approvals In September 2026

The FDA approved 13 drugs in September 2026, including Zanvastro (IONS) for Alexander disease, Omcazio (6620.TWO) for various cancers, Etcamah (AZN) for breast cancer, Pixclara (TLX) for glioma diagnosis, and ISEMBLYD (SRRK) for SMA. Key pricing and clinical data were reported.

rttnews.com3 min
OCT 8
$SRRKMed

Raymond James reiterates Scholar Rock stock rating on MAA resubmission

Raymond James reiterated a Strong Buy rating and $72.00 price target for Scholar Rock (SRRK) after its MAA resubmission for apitegromab in the EU. The stock trades at $41.99, down 8.6% in a week, with a $5.08B market cap. The company expects a regulatory opinion in early 2027. Analysts highlight the potential for significant non-U.S. revenue, with estimates ranging from $2.2B to $3.1B by 2035.

investing.com1 min
OCT 8
$SRRKMed

Scholar Rock Revives European Filing For SMA Therapy After U.S. Approval

Scholar Rock (SRRK) resubmitted its European application for apitegromab, a treatment for spinal muscular atrophy (SMA), after addressing a manufacturing issue. The resubmission includes a new facility and is supported by Phase 3 trial results showing motor function improvements. The EMA is expected to issue an opinion in 2027. SRRK shares are currently trading at $41.48, down 1.71%.

rttnews.com2 min
OCT 8
$SRRKMed

Scholar Rock Resubmits Apitegromab Marketing Authorisation Application (MAA) to European Medicines Agency (EMA) for Treatment of Children and Adults with Spinal Muscular Atrophy (SMA)

Scholar Rock (SRRK) resubmitted its Marketing Authorisation Application (MAA) for apitegromab to the European Medicines Agency (EMA) for treating spinal muscular atrophy (SMA). The resubmission includes an alternate fill-finish facility, aligning with EMA guidance. The company anticipates a CHMP opinion in H1 2027. Apitegromab, marketed as ISEMBYLD in the U.S., is the first muscle-targeted therapy to show motor function improvement in SMA patients.

biospace.com2 min
OCT 8
$SRRKMedAI 8/10

Scholar Rock resubmits EU application for SMA treatment

Scholar Rock (NASDAQ:SRRK) resubmitted its EU application for apitegromab, a treatment for spinal muscular atrophy, using an alternate fill-finish facility. The company withdrew its previous application due to GMP compliance issues. Scholar Rock anticipates a CHMP opinion in the first half of 2027. Apitegromab is FDA-approved in the U.S. under the brand name ISEMBYLD.

investing.com2 min